- Home
- LXRX vs QDEL Comparison
LXRX vs QDEL Comparison
Compare LXRX & QDEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXRX | QDEL |
|---|---|---|
| Founded | 1995 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 996.7M | 989.5M |
| IPO Year | 2000 | 2022 |
Fundamental Metrics
Financial Performance| Metric | LXRX | QDEL |
|---|---|---|
| Price | $1.60 | $14.08 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | $4.55 | ★ $14.67 |
| AVG Volume (30 Days) | ★ 2.6M | 1.8M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.78 | 45.35 |
| EPS | ★ N/A | N/A |
| Revenue | $49,803,000.00 | ★ $2,730,200,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 60.24 | N/A |
| 52 Week Low | $1.10 | $9.92 |
| 52 Week High | $2.68 | $35.58 |
Technical Indicators
Market Signals| Indicator | LXRX | QDEL |
|---|---|---|
| Relative Strength Index (RSI) | 34.71 | 60.91 |
| Support Level | $1.50 | $13.04 |
| Resistance Level | $1.81 | $17.86 |
| Average True Range (ATR) | 0.07 | 1.03 |
| MACD | -0.00 | 0.26 |
| Stochastic Oscillator | 27.20 | 87.17 |
Price Performance
Historical ComparisonAbout LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About QDEL QuidelOrtho Corporation
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.